Principal Financial Group
TCRR

Principal Financial Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Principal Financial Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,884
Closed -$213K – 2512
2020
Q4 		$213K Buy
+6,884
New +$174K ﹤0.01% 2310

Other funds holding TCRR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Principal Financial Group's TCRR Position: Q1 2021 in Review

Principal Financial Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2021, closing a stake of 6,884 shares — an estimated $213K sold.

Principal Financial Group first reported a position in TCRR in Q4 2020 and held it in 1 quarter. The position peaked at $213K in Q4 2020. 129 funds tracked by Wall St. Rank hold TCRR as of Q1 2021.

  • Principal Financial Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Principal Financial Group sold 6,884 TCR2 Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $213K.
  • Principal Financial Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Principal Financial Group's TCR2 Therapeutics Inc. Common Stock position peaked at $213K in Q4 2020.
  • 129 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2021.

Based on Principal Financial Group's 13F filing for Q1 2021, filed 10 May 2021.